Cytokines News and Research

Latest Cytokines News and Research

Medical student receives 2009 Lucien Rubenstein Award

The American Brain Tumor Association has announced that Alexander Ksendzovsky, a third-year medical student at the Chicago Medical School of Rosalind Franklin University in North Chicago, is the 2009 Lucien Rubenstein Award recipient.

21 Jan 2010

CytoDyn commences enrollment in Cytolin clinical trial

Following approval of the Institutional Review Board, CytoDyn, Inc. has discharged its duty to register a clinical trial of Cytolin®, the Company’s lead product, with the government’s website at www.clinicaltrials.gov, ID NCT01048372. The public has online access to this federal database, which describes the key elements of clinical trials and their status.

19 Jan 2010

Prescription drugs prove effective in managing moderate to severe psoriasis

Clinical trials to test the effectiveness of two prescription drugs for the debilitating skin condition psoriasis have revealed significant differences that should help inform physicians treating patients with the condition.

18 Jan 2010

M. D. Anderson researchers discover mechanism that helps glioblastomas evade immune attack

Cancer-initiating cells that launch glioblastoma multiforme, the most lethal type of brain tumor, also suppress an immune system attack on the disease, scientists from The University of Texas M. D. Anderson Cancer Center report in a paper featured on the cover of the Jan. 15 issue of Clinical Cancer Research.

18 Jan 2010

New findings may yield novel therapies for chronic neurodegenerative diseases

We all have at one time or another experienced the typical signs of an infection: the fever, the listlessness, the lack of appetite. They are orchestrated by the brain in response to circulating cytokines, the signaling molecules of the immune system. But just how cytokines' reach extends beyond the almost impenetrable blood-brain barrier has been the topic of much dispute.

18 Jan 2010

NeuroScience launches NEI Guided Nutrition Program

NeuroScience, Inc. has launched a comprehensive and customizable dietary program based on patients' food sensitivity test results. The NEI Guided Nutrition Program(TM) is the first offering through NeuroScience, Inc.'s new NEI Nutrition(TM) division.

12 Jan 2010

CEL-SCI completes validation of its GMP manufacturing facility

CEL-SCI Corporation, a late-stage oncology company and a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases, announced today it has completed the validation of all critical utilities and manufacturing equipment at its GMP manufacturing facility in Maryland.

12 Jan 2010

Immune cells causes inflammation in thyroid-associated ophthalmopathy

A cell type that causes significant scarring in lung disease appears to have a similar effect in Graves' disease, University of Michigan Health System researchers have found. The cells, called fibrocytes, are present at a higher than normal frequency in patients with Graves' disease, according to a new study, the first to associate fibrocytes with this autoimmune disease.

9 Jan 2010

Fibrocytes associated with Graves' disease

9 Jan 2010

Genentech's ACTEMRA approved to treat RA

Genentech, Inc., a wholly owned member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) approved ACTEMRA® (tocilizumab) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.

8 Jan 2010

LSUHSC receives $2.1 million grant for pneumonia research

Dr. Jay Kolls, Professor and Chairman of Genetics at the LSU Health Sciences Center New Orleans School of Medicine, has been awarded a $2.1 million grant over five years by the National Heart, Lung, and Blood Institute of the National Institutes of Health to further his work on a discovery that plays a critical role in the body's defense against pneumonia.

8 Jan 2010

$HIV-infected postmenopausal women face higher risk for accelerated bone loss and fracture$

HIV-infected postmenopausal women face higher risk for accelerated bone loss and fracture

According to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM), postmenopausal HIV-infected women have a high prevalence of low bone mineral density and high bone turnover placing them at high risk for future bone fractures.

5 Jan 2010

Phase 2 study evaluating VBL Therapeutics' lead compound VB-201 initiated

VBL Therapeutics today announced the initiation of a Phase 2 efficacy and safety study evaluating lead compound VB-201 for the treatment of patients with psoriasis. VB-201 is poised to be a first-in-class, orally-administered immune response modifier expected to reduce inflammation in a broad range of conditions such as psoriasis.

5 Jan 2010

Gene's role in immune system may suggest new treatments for childhood asthma

Pediatric researchers have identified a novel gene involved in childhood asthma, in one of the largest gene studies to date of the common respiratory disease. Because the gene, called DENND1B, affects cells and signaling molecules thought to be instrumental in the immune system overreaction that occurs in asthma, the discovery may have singled out an important target for new treatments.

23 Dec 2009

Positive interim results from Idera Pharmaceuticals' IMO-2125 Phase 1 clinical trial for HCV

Idera Pharmaceuticals, Inc. today announced positive interim results from a Phase 1 clinical trial of IMO-2125 in patients with chronic hepatitis C virus infection (HCV). IMO-2125 is an agonist of Toll-like Receptor 9 that Idera designed to treat HCV by inducing endogenous interferon-alpha and other Th1-type cytokines and chemokines.

21 Dec 2009

Organogenesis files a PMA with the FDA for its CelTx living cell-based technology

Organogenesis, Inc. announced today that it has filed a Premarket Approval Application (PMA) with the U.S. Food and Drug Administration (FDA) for its CelTx(TM), a living cellular construct for oral soft tissue regeneration. If approved, CelTx will be the first, living cell-based technology that is FDA-approved for use in the dental market.

21 Dec 2009

Eli Lilly, Incyte announce collaboration for development and commercialization of INCB28050 oral inhibitor

Eli Lilly and Company and Incyte Corporation announced today that they have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of Incyte's oral JAK1/JAK2 inhibitor, INCB28050, and certain follow on compounds, for inflammatory and autoimmune diseases. The lead compound, INCB28050, is currently being studied in a six-month dose-ranging Phase II trial for rheumatoid arthritis.

21 Dec 2009

UAB professors honored for scientific contributions and outstanding mentorship

Three University of Alabama at Birmingham (UAB) professors have been elected fellows of the American Association for the Advancement of Science (AAAS).

18 Dec 2009

SOCS1 molecule prevents cancer-causing activity of cytokines, discover researchers

Canadian researchers have discovered a novel molecular mechanism that prevents cancer. In the December 11 edition of the prestigious journal Molecular Cell, scientists from the Universit- de Montr-al and the Universit- de Sherbrooke explain how they found that the SOCS1 molecule prevents the cancer-causing activity of cytokines, hormones that are culprits in cancer-prone chronic inflammation diseases such as Crohns, in smokers and people exposed to asbestos.

12 Dec 2009

Mouse study suggests response to injury-induced growth factors can be revived

Brain and spinal-cord injuries typically leave people with permanent impairment because the injured nerve fibers (axons) cannot regrow. A study from Children's Hospital Boston, published in the December 10 issue of the journal Neuron, shows that axons can regenerate vigorously in a mouse model when a gene that suppresses natural growth factors is deleted.

10 Dec 2009